Intervention

Eculizumab

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions17

Lead sponsors shown3

Clinical trials

3 shown

Complement Regulation to Undo Systemic Harm in PreeclampsiaNCT04725812 · 2021-09-13

TERMINATED

The Use of Eculizumab in HELLP SyndromeNCT04103489 · 2021-02-23

COMPLETED

Complement Inhibitor Eculizumab in Clinical Islet TransplantationNCT02727608 · 2016-05-15

COMPLETED

Common conditions

Complement Abnormality2 AHUS1 Complement Regulatory Factor Defect1 Diabetes Mellitus1 Eculizumab1 HELLP1 HELLP Syndrome1 HELLP Syndrome (HELLP), Third Trimester1 HELLP Syndrome Second Trimester1 HELLP Syndrome Third Trimester1 Maternal Injury1 Morbidity;Newborn1 PNH1 Preeclampsia1 Preeclampsia Severe1 Pregnancy Related1 Severe Preeclampsia1

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

atypical hemolytic-uremic syndrome1 diabetes mellitus1 HELLP syndrome1 paroxysmal nocturnal hemoglobinuria1 preeclampsia1 severe pre-eclampsia1

Leading sponsors

Cedars-Sinai Medical Center 1 Johns Hopkins University 1 Uppsala University 1

Trial status mix

COMPLETED2

TERMINATED1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.